Santhera Pharmaceuticals Holding AG (LON:0QN1)
15.02
-0.06 (-0.40%)
At close: Jul 31, 2025
Santhera Pharmaceuticals Holding AG Employees
Santhera Pharmaceuticals Holding AG had 79 employees as of December 31, 2024. The number of employees increased by 34 or 75.22% compared to the previous year.
Employees
79
Change (1Y)
34
Growth (1Y)
75.22%
Revenue / Employee
$436,461
Profits / Employee
-$468,339
Market Cap
178.54M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 79 | 34 | 75.22% |
Dec 31, 2023 | 45 | -1 | -2.18% |
Dec 31, 2022 | 46 | 6 | 16.24% |
Dec 31, 2021 | 39 | -47 | -54.19% |
Dec 31, 2020 | 86 | -27 | -23.83% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Oxford Nanopore Technologies | 1,382 |
Santhera Pharmaceuticals Holding AG News
- 3 months ago - Santhera Pharmaceuticals reports FY results - Seeking Alpha
- 5 months ago - Santhera Pharmaceuticals reports FY results - Seeking Alpha
- 7 months ago - Santhera Pharmaceuticals Provides Update on Royalty Agreement for AGAMREE® (Vamorolone) and Warrants held by Idorsia - GlobeNewsWire
- 7 months ago - Santhera Enters into Supply and Distribution Agreement for AGAMREE® (Vamorolone) with Clinigen Group - GlobeNewsWire
- 8 months ago - Santhera Announces Approval from China's NMPA for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy - Benzinga
- 11 months ago - Santhera Enters into an Exclusive Distribution Agreement with GENESIS Pharma for AGAMREE® (Vamorolone) in Central and Eastern Europe - GlobeNewsWire